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Abstract. An efficient approach to reversed nucleosides which enables their synthesis in gram quantities is 
described. N-1′-Pyrimidine reversed nucleosides were prepared by treating of the sodium salt of pyrimi-
dine bases with protected 5-tosyl ribose. Additionally, N-1′,N-3′-disubstituted reversed nucleosides were 
isolated in the condensation reactions with the 5-halogen pyrimidines. Using the Sonogashira coupling of 
5′-iodouracil reversed nucleoside with ethynyltrimethyl silane gave 5′-ethynyl derivative which was fur-
ther transformed into 5′-acetyl reversed nucleoside. Biological activity of deprotected reversed nucleo-
sides was validated on the panel of six human carcinoma cell lines (HeLa, MIAPaCa2, Hep2, NCI-H358, 
CaCo-2, and HT-29). 5′-Iodouracil derivative displayed moderate growth inhibition activity against hu-
man colon carcinoma (CaCo-2) cells. 
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INTRODUCTION 
Modified nucleosides represent a well known class of 
chemotherapeutic agents for treatment of viral1−4 and 
cancer5,6 diseases. In the quest for new derivatives with 
a potent biological activity, many structural variations at 
the base and/or sugar moiety of natural nucleosides have 
been explored.7,8 The practical applicability of nucleo-
side analogues in chemotherapy largely depends on the 
stability of the drug in organism, because their catabo-
lism usually includes degradation of nucleosidic link-
age. Reversed or iso-nucleosides constitute a class of 
nucleoside analogues in which the nucleobase is linked 
to the sugar moiety through a carbon atom other than 
ribofuranose-C1. Hence, this class of compounds ap-
pears particularly interesting as drug candidates9−13 due 
to the lack of glycosidic linkage which makes them 
more stable to hydrolytic cleavage. In addition, the 
reversed nucleosides represent the largest pool of chiral 
synthons for the synthesis of aliphatic nucleoside ana-
logues.14−20 
In our previous communication we have reported 
on the synthesis of several partially and fully deprotect-
ed reversed and double headed nucleosides the former 
incorporating uracil or 5-iodouracil attached by N1′ at 
the C5 position of ribofuranose.19,21 In this work we 
present detailed experimental conditions for the synthe-
sis of such reversed nucleosides and extend the synthe-
sis to the highly interesting reversed nucleoside 13 in-
corporating 5-fluorouracil, the well-known anticancer 
drug. We also report on the preparation of the novel 
type of the nucleoside derivatives 9, 11 and 15 contain-
ing the ribose fragments attached at both, the N1′ and 
N3′ positions of 5′-iodo and 5′-fluorouracil bases. The 
example of further synthetic modification of the re-
versed 5′-iodouracil nucleoside 10 into protected 5′-
ethinyl derivative 16 by the Sonogashira coupling reac-
tion is also presented. Upon deprotection it becomes a 
versatile synthon for the click chemistry. The described 
synthetic studies enabling preparation of reversed nu-
cleosides in the gram scale quantities are the prerequi-
site for biological testing and also open new perspec-
tives for their synthetic transformations into novel opti-
cally active aliphatic or double headed nucleoside ana-
logues, or sulfonamido and 1,2,3-triazolyl substituted 
reversed nucleoside derivatives.22 The prepared reversed 
nucleosides were tested for the antiproliferative activity 
on the panel of six human carcinoma cell lines (HeLa, 
MIAPaCa2, Hep2, NCI-H358, CaCo-2, and HT-29) and 
5′-iodouracil derivative 14 showed promising growth 
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inhibition activity against human colon carcinoma (Ca-
Co-2) cells. 
 
EXPERIMENTAL 
General 
Solvents were distilled from appropriate drying agents 
shortly before use. TLC was carried out on DC-
plastikfolien Kieselgel 60 F254 and preparative thick 
layer (2 mm) chromatography was done on Merck 60 
F254. Flash column chromatography was performed on 
silica gel Merck 0.040−0.063 mm. Melting points were 
determined on a Kofler hot-stage apparatus and were 
uncorrected. UV Spectra were taken on a Philips 
PU8700 UV/VIS spectrophotometer. IR spectra were 
obtained as KBr pellets on a Perkin-Elmer 297 spectro-
photometer. 1H and 13C NMR spectra were recorded in 
DMSO-d6 or CDCl3 on Varian Gemini 300 (300/75 
MHz) or Bruker AV 300 and 600 MHz spectrometers 
using TMS or DMSO-d6 as the internal standard. The 
order of C-atoms and protons were confirmed on the 
basis of 2D NMR HETCOR, COSY, and NOESY. Ele-
mental analyses were done on a Perkin-Elmer 2400 
Series II CHNS analyzer. 
 
The Following Compounds were Prepared according 
to Literature Procedures 
Methyl 2,3-O-isopropylidene--D-ribofuranoside (2)23,24 
From D-ribose 1 (5.3 g, 32.84 mmol), compound 2 was 
obtained in 73 % yield (4.99 g) as oil: 
1H NMR (CDCl3) δ/ppm: 4.97 (s, 1H, H-1), 4.82 (d, 1H, 
J = 6.0 Hz, H-2), 4.59 (d, 1H, J = 6.0 Hz, H-3), 4.40 (t, 
1H, J = 3.1 Hz, OH), 3.64 (m, 2H, H-4, H-5a), 3.46 (m, 
1H, H-5b), 3.42 (s, 3H, OCH3), 1.49 (s, 3H, CCH3), 1.32 
(s, 3H, CCH3); 13C NMR (CDCl3) δ/ppm: 112.03 (s, 
O−C−O), 110.01 (s, C-1), 84.92 (d, C-4), 85.85 (d, C-
3), 82.00 (d, C-2), 64.02 (t, C-5), 55.59 (q, OCH3), 
26.50 (q, CCH3), 24.81 (q, CCH3).  
Methyl 2,3-O-isopropylidene-5-O-p-toluenesulfonyl--
D-ribofuranoside (3)23,24 
From protected methyl ribofuranoside 2 (4.99 g, 24.43 
mmol) compound 3 was obtained in 76 % yield (6.7 g) 
as a white crystals: Rf = 0.3 (CH2Cl2/MeOH 20:1); m.p. 
= 77−82 °C; 1H NMR (DMSO-d6) δ/ppm: 7.80 (d, 2H, J 
= 8.3 Hz, Ph), 7.50 (d, 2H, J = 8.0 Hz, Ph), 4.91 (s, 1H, 
H-1), 4.62 (d, 1H, J = 5.9 Hz, H-2), 4.50 (d, 1H, J = 5.9 
Hz, H-3), 4.20 (t, 1H, J = 7.0 Hz, H-4), 4.05 (d, 2H, J = 
7.0 Hz, 2 H-5), 3.10 (s, 3H, OCH3), 2.42 (s, 3H, CH3-
Ph), 1.35 (s, 3H, CCH3), 1.21 (s, 3H, CCH3); 13C NMR 
(DMSO-d6) δ/ppm: 145.67 (s, Ph), 132.52 (s, Ph), 
130.71 (d, Ph), 128.16 (d, Ph), 112.20 (s, O−C−O), 
109.25 (d, C-1), 84.61 (d, C-4), 83.61(d, C-2), 80.92 (d, 
C-3), 70.81 (t, C-5), 54.77 (q, OCH3), 26.61 (q, CCH3), 
25.04 (q, CCH3), 21.55 (q, Ph-CH3).  
5-Iodopyrimidine-2,4(1H,3H)-dione (6)25−27 
From uracil 4 (5 g, 0.045 mol) compound 6 was ob-
tained in 86 % yield (9.1 g) as a white crystals: 1H NMR 
(DMSO-d6) δ/ppm: 11.43 (brs, 1H, NH-3), 11.14 (brs, 
1H, NH-1), 7,87 (d, 1H, J = 5.9 Hz, H-6); 13C NMR 
(DMSO-d6) δ/ppm: 161.38 (s, C-4), 151.16 (s, C-2), 
146.92 (d, C-6), 67.41 (s, C-5). 
 
General Procedures for the Preparation of Reversed 
Nucleosides 7−11 
The sodium salt of base was prepared by stirring a sus-
pension of an equimolar amount of the pyrimidine base 
4−6 (1 mmol) and sodium hydride (50 % in oil suspen-
sion, 1 mmol) in DMF (3−4 mL/mmol) at room temper-
ature for 1 h and warming at 60−80 °C for 0.5 h. A 
solution of the methyl 2,3-O-isopropylidene-5-O-p-
toluenesulfonyl--D-ribofuranoside (3) (0.8 mmol) in 
DMF (1.7 mL/mmol of sugar) was added dropwise to 
this suspension at room temperature. The reaction mix-
ture was stirred and heated at 100 oC for 20 hours. The 
resulting clear solution was evaporated and the residue 
was dissolved in hot chloroform. The suspension was 
filtered through Celite and filtrate was washed with 
water, dried over Na2SO4 and evaporated.  
Methyl 5-deoxy-5-(2,4-dioxopyrimidin-1H-1-yl)-2,3-O-
isopropylidene--D-ribofuranoside (7) 
Method A: Following the general procedure from uracil 
4 (1.8 g, 16 mmol) and after purification of the crude 
mixture by flash chromatography (CH2Cl2:MeOH 60:1), 
compound 7 (1.42 g) was obtained in a yield of 37 %, as 
a white solid: Rf = 0.26 (CH2Cl2/MeOH 20:1); m.p. 
187−188 °C; UV (96 % EtOH) λmax/nm: 207, 228 and 
263, log ε/dm3 mol−1 cm−1: 3.96, 3.39 and 4.03; IR(KBr) 
ῦmax/cm−1: 3145 (w), 3090 (m), 2995 (m), 2925 (m), 
1740 (s), 1705 (s), 1465 (s), 1420 (m), 1375 (m), 1245 
(m), 1215 (m), 1090 (m), 1060 (m), 1025 (m), 955 (m); 
1H NMR (CDCl3) δ/ppm: 9.38 (brs, 1H, NH-3'), 7.25 (d, 
1H, J = 7.9 Hz, H-6'), 5.71 (dd, 1H, J = 7.9 Hz, J = 2.1 
Hz, H-5'), 5.00 (s, 1H, H-1), 4.65 (brs, 2H, H-2 and H-
3), 4.49 (dd, 1H, J = 5.3, J = 8.2 Hz, H-4), 4.21 (dd, 1H, 
J = 5.3, J = 13.8 Hz, H-5a), 3.43 (dd, 1H, J = 8.2, J = 
13.8 Hz, H-5b), 3.41 (s, 3H, OCH3), 1.47 (s, 3H, CCH3), 
1.32 (s, 3H, CCH3); 13C NMR (CDCl3) δ/ppm: 163.71 
(s, C-4'), 150.90 (s, C-2'), 145.04 (d, C-6'), 112.92 (s, 
O−C−O), 110.61 (d, C-1), 102.03 (d, C-5'), 84.93 (d, C-
3), 84.37 (d, C-4), 81.83 (d, C-2), 55.93 (q, OCH3), 
51.47 (t, C-5), 26.41 (q, CCH3), 25.00 (q, CCH3). Anal. 
Calcd. mass fractions of elements, w/%, for C13H18N2O6 
(Mr = 298.29) are: C 52.34, H 6.08, N 9.39; found: C 
52.14, H 6.21, N 9.5. 
Method B: Compound 10 (143 mg, 0.34 mmol) was 
dissolved in methanol (50 mL) and 0.1 M aqueous 
NaOH (3.4 mL) was added. The reaction mixture was 
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cooled to 5 oC and purged with argon. Palladium on 
carbon catalyst (79 mg) was added and the reaction 
mixture was treated with hydrogen gas (42 psi) in a Parr 
hydrogenation apparatus for 4 h. The mixture was fil-
tered through a Celite pad and washed with boiling 
methanol (20 mL). The combined methanol filtrates 
were concentrated under reduced pressure, dissolved in 
dichloromethane, washed with water, dried over Na2SO4 
and evaporated. The product was crystallized from 
methanol to afford 82.6 mg (82 %) of 3. The spectral 
properties were identical with a sample synthesized by 
method A.  
Methyl 5-deoxy-5-(2,4-dioxo-5-fluoropyrimidin-1H-1-
yl)-2,3-O-isopropylidene--D-ribofuranoside (8) and 5-
fluoro-1,3-bis(tetrahydro-4-methoxy-2,2-dimethyl-
furo[3,4-d][1,3]dioxol-6-yl)methylpyrimidine-
2,4(1H,3H)-dione (9) 
Following the general procedure from 5-fluorouracil 5 
(1.2 g, 9.2 mmol) and after purification of the crude 
mixture by flash chromatography (CH2Cl2/MeOH 60:1), 
N-1′-regioisomer 8 (537 mg) was obtained in a yield of 
23 % and N-1′,N-3′-disubstituted nucleoside 9 (931 mg) 
was obtained in a yield of 25 %, both in the form of 
foam: 
N-1′-regioisomer 8: Rf = 0.51 (CH2Cl2/MeOH 
20:1); UV (MeOH) max 237 and 288 nm, log ε/dm3 
mol−1 cm−1: 4.02 and 4.11; IR(KBr) ῦmax/cm−1: 3450 (w), 
3220 (w), 3090 (w), 3080 (w), 2940 (w), 1741 (s), 1665 
(s), 1385 (m), 1240 (m), 1215 (m), 1005 (m), 1090 (m); 
1H NMR (DMSO-d6) δ/ppm: 11.87 (s, 1H, NH-3'), 8.08 
(d, 1H, JH-F = 6.9 Hz, H-6'), 4.95 (s, 1H, H-1), 4.74 (d, 
1H, J = 6.0 Hz, H-2), 4.62 (d, 1H, J = 5.9 Hz, H-3), 4.34 
(t, 1H, J = 7.2 Hz, H-4), 3.86 (dd, 1H, J = 13.9, J = 7.6 
Hz, H-5a), 3.59 (dd, 1H, J = 13.9, J = 6.9 Hz, H-5b), 
3.28 (s, 3H, OCH3), 1.37 (s, 3H, CCH3), 1.25 (s, 3H, 
CCH3); 13C NMR (DMSO-d6) δ/ppm: 157.71 (d, JC-F = 
26 Hz, C-4'), 150.11 (s, C-2'), 139.85 (d, JC-F = 230 Hz, 
C-5'), 130.38 (d, JC-F = 34 Hz, C-6'), 111.94 (s, 
O−C−O), 109.43 (d, C-1), 84.72 (d, C-3), 83.45 (d, C-
4), 81.32 (d, C-2), 54.99 (q, OCH3), 50.37 (t, C-5), 
26.31 (q, CCH3), 24.84 (q, CCH3). Anal. Calcd. mass 
fractions of elements, w/%, for C13H17N2O6F (Mr = 
316.28) are: C 49.37, H 5.42, N 8.86; found: C 49.19, H 
5.36, N 8.90. 
N-1′,N-3′-disubstituted nucleoside 9: Rf = 0.72 
(CH2Cl2/MeOH 20:1); UV (MeOH) max 238 and 290 
nm, log ε/dm3 mol−1 cm−1: 3.92 and 3.98; IR(KBr) 
ῦmax/cm−1: 3090 (w), 3080 (w), 2940 (w), 1740(s), 1660 
(s), 1465 (m), 1380 (m), 1245 (m), 1210 (m), 1166 (m), 
1015 (m), 1090 (m); 1H NMR (DMSO-d6) δ/ppm: 8.19 
(d, 1H, JH-F = 6.5 Hz, H-6'), 4.95 (s, 1H, H-1), 4.93 (s, 
1H, H-1''), 4.76 (d, 1H, J = 5.9 Hz, H-2), 4.69 (d, 1H, J 
= 5.9 Hz, H-2''), 4.62 (d, 1H, J = 5.9 Hz, H-3), 4.60 (d, 
1H, J = 5.9 Hz, H-3''), 4.38 (t, 1H, J = 7.2 Hz, H-4), 
4.24 (dd, 1H, J = 9.0 Hz, J = 4.9 Hz, H-4''), 4.80 (dd, 
1H, J = 13.2 Hz, J = 9.2 Hz, H-5''a ), 4.01 (dd, 1H, J = 
14.0 Hz, J = 6.7 Hz, H-5a), 3.90 (dd, 1H, J = 13.2, 5.0 
Hz, H-5''b), 3.70 (dd, 1H, J = 14.0 Hz, J = 7.6 Hz, H-
5b), 3.30 (s, 3H, OCH3), 3.28 (s, 3H, OCH3), 1.37 (s, 
3H, CCH3), 1.34 (s, 3H, CCH3), 1.25 (s, 3H, CCH3), 
1.22 (s, 3H, CCH3); 13C NMR (DMSO-d6) δ/ppm: 
159.97 (s, C-4'), 150.99 (s, C-2'), 149.15 (d, C-6'), 
128.26 (d, C-5'), 111.61 (s, O−C−O), 111.46 (s, 
O−C−O), 109.46 (d, C-1), 108.2 (d, C-1''), 84.60 (d, C-3 
or C-3 ''), 84.50 (d, C-3 or C-3''), 83.13 (C-4 and C-4''), 
81.69 (C-2 or C-2''), 81.11 (C-2'' or C-2), 55.06 (q, 
OCH3), 54.50 (q, OCH3), 51.52 (t, C-5), 44.55 (t, C-5''), 
26.24 (q, CCH3), 24.72 (q, CCH3). Anal. Calcd. mass 
fractions of elements, w/%, for C22H31N2O10F (Mr = 
502.49) are: C 52.59, H 6.22, N 5.57; found: C 52.65, H 
6.30, N 5.58.  
Methyl 5-deoxy-5-(2,4-dioxo-5-iodopyrimidin-1H-1-yl)-
2,3-O-isopropylidene--D-ribofuranoside (10) and 5-
iodo-1,3-bis(tetrahydro-4-methoxy-2,2-dimethyl-
furo[3,4-d][1,3]dioxol-6-yl)methylpyrimidine-
2,4(1H,3H)-dione (11) 
Following the general procedure from 5-iodouracil 6 
(1.55 g, 6.5 mmol) and after purification of the crude 
mixture by flash chromatography (CH2Cl2/MeOH 60:1), 
N-1′-regioisomer 10 (1.27 g) was obtained in a yield of 
58 % as a white solid and N-1′,N-3′-disubstituted nucle-
oside 11 (47 mg) was obtained in a yield of 1.5 % as a 
yellow foam. 
N-1′-regioisomer 10: Rf = 0.37 (CH2Cl2/MeOH 
20:1); m.p. 182−183 °C; UV(MeOH) λmax/nm: 215 and 
288, log ε/dm3 mol−1 cm−1: 4.13 and 3.91; IR (KBr) 
ῦmax/cm−1: 3190 (m), 3100 (m), 3050 (m), 2995 (m), 
1715 (s), 1655 (s), 1655 (s), 1450 (m), 1435 (m), 1400 
(m), 1385 (m), 1360 (m), 1345 (m), 1240 (m), 1200 (m) 
965 (m); 1H NMR (DMSO-d6) δ/ppm: 11.70 (brs, 1H, 
NH-3'), 8.10 (s, 1H, H-6'), 4.95 (s, 1H, H-1), 4.74 (d, 
1H, J = 5.8 Hz, H-2), 4.62 (d, 1H, J = 5.8 Hz, H-3), 
4.35 (m, 1H, H-4), 3.94 (dd, 1H, J = 6.7 Hz, J = 13.8 
Hz, H-5a), 3.62 (dd, 1H, J = 7.6 Hz, J = 13.8 Hz, H-
5b), 3.31 (s, 3H, OCH3), 1.37 (s, 3H, CCH3), 1.26 (s, 
3H, CCH3); 13C NMR (DMSO-d6) δ/ppm: 160.81 (s, C-
4'), 150.67 (s, C-2'), 150.15 (d, C-6'), 111.66 (s, O-C-
O), 109.37 (d, C-1), 84.51 (d, C-3), 83.24 (d, C-4), 
81.05 (d, C-2), 68.08 (s, C-5'), 55.05 (q, OCH3), 50.41 
(t, C-5), 26.21 (q, CCH3), 24.72 (q, CCH3). Anal. 
Calcd. mass fractions of elements, w/%, for 
C13H17N2O6I (Mr = 424.19) are: C 36.81, H 4.04, N 
6.61; found: C 36.65, H 3.96, N 6.78. 
N-1′,N-3′-disubstituted nucleoside 11: Rf = 0.62 
(CH2Cl2/MeOH 20:1); UV(MeOH) λmax/nm: 217 and 
290 (log ε/dm3 mol−1 cm−1: 4.02 and 3.97); IR (KBr) 
ῦmax/cm−1: 2990 (m), 2970 (m), 1710 (s), 1665 (br, s), 
1630 (m), 1445 (br, m), 1385 (m), 1375 (m), 1340 (w), 
1275 (m), 1240 (m), 1215 (m), 1160 (br, s), 870 (s); 1H 
NMR (DMSO-d6) δ/ppm: 8.19 (s, 1H, H-6'), 4.95 (s, 
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1H, H-1), 4.93 (s, 1H, H-1''), 4.76 (d, 1H, J = 5.9 Hz, H-
2), 4.69 (d, 1H, J = 5,9 Hz, H-2''), 4.62 (d, 1H, J = 5.9 
Hz, H-3), 4.60 (d, 1H, J = 5.9 Hz, H-3''), 4.38 (pt, 1H, J 
= 7.2 Hz, H-4), 4.24 (dd, 1H, J = 9.0, 4.9 Hz, H-4''), 
4.08 (dd, 1H, J = 13.2, 9.2 Hz, H-5''a), 4.01 (dd, 1H, J = 
14.0, 6.7 Hz, H-5a), 3.90 (dd, 1H, J = 13.2, 5.0 Hz, H-
5''b), 3.70 (dd, 1H, J = 14.0, 7.6 Hz, H-5b), 3.30 (s, 3H, 
OCH3), 3.28 (s, 3H, OCH3 ), 1.37 (s, 3H, OCH3), 1.34 
(s, 3H, OCH3), 1.25 (s, 3H, OCH3), 1.22 (s, 3H, OCH3); 
13C NMR (DMSO-d6) δ/ppm: 159.97 (s, C-4'), 150.99 
(s, C-2'), 149.08 (d, C-6'), 111.62 (s, O−C−O), 111.46 
(s, O−C−O), 109.46 (d, C-1), 108.72 (d, C-1''), 84.60 (d, 
C-3), 84.50 (d, C-3''), 83.13 (brd, C-4, C-4''), 81.69 (d, 
C-2), 81.11 (d, C-2''), 67.11 (s, C-5'), 55.07 (q, OCH3), 
54.51 (q, OCH3), 51.52(t, C-5), 44.55 (t, C-5''), 26.24 
(q, CCH3), 26.20 (q, CCH3), 24.72 (q, CCH3). Anal. 
Calcd. mass fractions of elements, w/%, for 
C22H31N2O10I (Mr = 610.39) are: C 43.29, H 5.12, N 
4.59; found: C 43.15, H 5.07, N 4.70. 
 
General Procedure for the Hydrolysis of Isopropy-
lidene Protecting Group of Reversed Nucleosides 
7−10 and 17 
To a solution of reversed nucleoside (1 mmol) in meth-
anol (11−15 mL/mmol) Amberlite IR-120 (H+) ion 
exchange resin (3.3 g/mmol), that has been washed 
several times with absolute methanol, was added. The 
mixture was refluxed for 8 h, cooled and filtered 
through a Celite pad, and the resin was washed with 
methanol (≈20 mL). The filtrate and washings were 
combined and evaporated.  
Methyl 5-deoxy-5-(2,4-dioxopyrimidin-1H-1-yl)--D-
ribofuranoside (12) 
Following the general procedure from reversed nucleo-
side 7 (80 mg, 0.27 mmol) the resulting mixture was 
purified by preparative TLC with CH2Cl2/MeOH (9:1) 
as eluents. The major band was eluted, evaporated to 
afford 62 mg (89 %) of 12 as a foam: Rf = 0.32 
(CH2Cl2/MeOH 9:1); UV(MeOH) λmax/nm: 208 and 
265, log ε/dm3 mol−1 cm−1: 3.72 and 3.80; IR (KBr) 
ῦmax/cm−1: 3420 (s), 2940 (m), 1685 (s), 1530 (m), 1385 
(m), 1350 (m), 1255 (m) 1130 (m), 1085 (m), 1025 (m); 
1H NMR (DMSO-d6) δ/ppm: (anomers β: 10:1) β-
anomer: 11.40 (brs, 1H, NH-3'), 7.50 (d, 1H, J = 7.9 Hz, 
H-6'), 5.54 (d, 1H, J = 7.9 Hz, H-5'), 5.08 (brs, 2H, OH-
2 and OH-3), 4.83 (s, 1H, H-1), 4.01−3.62 (m, 5H, H-2, 
H-3, H-4 and 2 H-5), 3.40 (s, 3H, OCH3); 13C NMR 
(DMSO-d6) δ/ppm: (β-anomer) 163.94 (s, C-4'), 151.18 
(s, C-2'), 146.62 (d, C-6'), 108.58 (d, C-1), 100.62 (d, C-
5') 79.63 (d, C-4), 74.38 (d, C-2), 72.46 (d, C-3), 54.97 
(q, OCH3), 50.74 (t, C-5). Anal. Calcd. mass fractions of 
elements, w/%, for C10H14N2O6 (Mr = 258.23) are: C 
46.51, H 5.46, N 10.85; found: C 46.31, H 5.69, N 
10.73. 
Methyl 5-deoxy-5-(2,4-dioxo-5-fluoropyrimidin-1H-1-
yl)--D-ribofuranoside (13) 
Following the general procedure from reversed nucleo-
side 8 (250 mg, 0.79 mmol) the product 13 was obtained 
in 79 % (72 mg) yield as a foam: Rf = 0.21 
(CH2Cl2/MeOH 9:1); UV (MeOH) λmax/nm: 235 and 
288, log ε/dm3 mol−1 cm−1: 3.90 and 4.10; IR(KBr) 
ῦmax/cm−1: 3445 (m), 3210 (m), 3080 (w), 2945 (w), 
1745 (s), 1665 (s), 1475 (w), 1380 (m), 1230 (m), 1210 
(m), 1150 (w), 1130 (m), 1045 (m), 1035 (w); 1H NMR 
(DMSO-d6) δ/ppm: -anomer: 7.91 (d, 1H, JH-F = 6.8 
Hz, H-6'), 5.34−5.01 (brs, 1H, OH-2), 4.64 (s, 1H, H-
1), 4.12−3.57 (m, 6H, OH-3, H-2, H-3, H-4, 2H-5), 
3.25 (s, 3H, OCH3). 13C NMR (DMSO-d6) δ/ppm: -
anomer: 157.94 (d, 3JC-F = 23 Hz, C-4'), 150.11 (s, C-2'), 
139.31 (d, JC-F = 227 Hz, C-5'), 130.68 (d, 3JC-F = 34 Hz, 
C-6'), 108.45 (d, C-1), 79.36 (d, C-4), 74.26 (d, C-2), 
72.28 (d, C-3), 54.79 (q, OCH3), 50.42 (t, C-5); -
anomer: 13C NMR (DMSO-d6) δ/ppm: 157.94 (d, 3JC-F = 
23 Hz, C-4'), 150.11 (s, C-2'), 139.31 (d, JC-F = 227 Hz, 
C-5'), 130.68 (d, 3JC-F = 34 Hz, C-6'), 102.83 (d, C-1), 
81.00 (d, C-4), 70.99 (d, C-3 or C-2), 70.04 (d, C-3 or 
C-2), 54.83 (q, OCH3), 50.42 (t, C-5). Anal. Calcd. mass 
fractions of elements, w/%, for C10H13N2O6F (Mr = 
276.22) are: C 43.48, H 4.74, N 10.14; found: C 43.51, 
H 4.70, N 10.19. 
 
Methyl 5-deoxy-5-(2,4-dioxo-5-iodopyrimidin-1H-1-yl)-
-D-ribofuranoside (14) 
Following the general procedure from reversed nucleo-
side 10 (498 mg, 1.15 mmol) the product was crystal-
lized from methanol to afford 381 mg (89 %) of 14 as a 
white crystals: Rf = 0.48 (CH2Cl2/MeOH 9:1); m.p. 
99−101 °C; UV(MeOH) λmax/nm: 213 and 287, log 
ε/dm3 mol−1 cm−1: 4.14 and 3.98; IR (KBr) ῦmax/cm−1: 
3430 (m), 3050 (w), 2970 (w), 1730 (s), 1715 (s), 1665 
(s), 1610 (m), 1445 (w), 1420 (w), 1340 (w), 1300 (w), 
1255 (m), 1125 (m), 1100 (w), 1080 (w), 1025 (m); 1H 
NMR (DMSO-d6) δ/ppm: (anomers β: 10:1) β-anomer: 
11.65 (brs, 1H, NH-3'), 8.02 (s, 1H, H-6'), 5.13 (d, 1H, J 
= 4.1 Hz, OH-2), 4.99 (d, 1H, J = 5.3 Hz, OH-3), 4.64 
(s, 1H, H-1), 4.06−3.68 (m, 5H, H-2, H-3, H-4 and 2H-
5), 3.25 (s, 3 H, CH3O); 13C NMR (DMSO-d6) δ/ppm: 
(β-anomer) 161.06 (s, C-4'), 150.85 (s, C-2'), 150.85 (d, 
C-6'), 108.64 (d, C-1), 79.69 (d, C-4), 74.44 (d, C-2), 
72.18 (d, C-3), 67.50 (s, C-5'), 55.14 (q, CH3O), 50.17 
(t, C-5). Anal. Calcd. mass fractions of elements, w/%, 
for C10H13N2O6I (Mr = 384.12) are: C 31.27, H 3.41, N 
7.29; found: C 31.41, H 3.68, N 7.37.  
5-Fluoro-1,3-bis(tetrahydro-3,4-dihydroxy-5-metho-
xyfuran-2-yl)methylpyrimidine-2,4(1H,3H)-dione (15) 
Following the general procedure from reversed nucleo-
side 9 (385 mg, 0.77 mmol) the product 15 was obtained 
in 65 % (210 mg) yield as a foam: Rf = 0.35 
(CH2Cl2/MeOH 9:1); UV (MeOH) λmax/nm: 237 and 
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291, log ε/dm3 mol−1 cm−1: 3.91 and 4.10; IR(KBr) 
ῦmax/cm−1: 3440 (m), 3215 (m), 3000 (w), 2945 (w), 
1740 (s), 1655 (s), 1455 (w), 1370 (m), 1230 (m), 1210 
(m), 1135 (m), 1040 (m), 1030 (w), 955 (w); 1H NMR 
(DMSO-d6) δ/ppm: (anomers β: 10:3) β-anomer: 8.07 
(d, 1H, J = 6.4 Hz, H-6'), 8.03 (d, 1H, J = 6.5 Hz, H-
6), 5.08 (brs, 4H, OH), 4.64 (s, 1H, H-1), 4.59 (s, 1H, 
H-1''), 4.14−3,29 (m, 10H, H-2, H-3, H-4, 2H-5, H-2'', 
H-3'', H-4'', 2H-5''), 3.26 (s, 3H, OCH3), 3.23 (s, 3H, 
OCH3); 13C NMR (DMSO-d6) δ/ppm: (β-anomer) 
156.84 (d, 3JC-F = 15 Hz, C-4'), 149.66 (s, C-2'), 140.14, 
138.64 (d, JC-F = 226 Hz, C-5'), 129.64 (d, JC-F = 33 Hz, 
C-6'), 108.50 (d, C-1), 108.20 (d, C-1''), 79.22 (d, C-4), 
78.18 (d, C-4''), 74.50 (d, C-2 or 2''), 74.28 (d, C-2 or 
2''), 73.40 (d, C-3 or C-3''), 72.32 (d, C-3 or C-3''), 54.84 
(q, OCH3), 54.39 (q, OCH3), 51.74 (t, C-5), 44.70 (t, C-
5''). Anal. Calcd. mass fractions of elements, w/%, for 
C16H23N2O10F (Mr = 422.36) are: C 45.50, H 5.49, N 
6.63; found: C 45.42, H 5.41, N 6.72.  
Methyl 5-deoxy-5-2,4-dioxo-5-[(2-trimethylsilyl)ethy-
nyl]pyrimidin-1H-1-yl-2,3-O-isopropylidene--D-
ribofuranoside (16) 
A suspension of 10 (200 mg, 0.47 mmol), 
bis(triphenylphosphine)palladium(II) chloride (33 mg, 
0.047 mmol) and cooper(I) iodide (0.9 mg, 0.0047 
mmol) in a degassed triethylamine (19 mL) was stirred 
vigorously and purged with argon. Excess ethynyltri-
methylsilane (55 mg, 0.56 mmol) was added and the 
reaction mixture was stirred under argon in an oil bath 
at 50 °C for 8 h. The reaction mixture was cooled and 
evaporated. The colored residue was dissolved in chlo-
roform (50 mL), washed with 5 % disodium 
EDTA/H2O (2x20 mL) and water (20 mL), dried over 
Na2SO4 and evaporated. The resulting mixture was 
purified by flash column chromatography on silica gel. 
The product was eluted with CH2Cl2/MeOH (20:1) and 
(9:1), evaporated and crystallized from chloroform to 
afford 132 mg (71 %) of 16 as a white crystals: Rf = 
0.39 (CH2Cl2/MeOH 20:1); m.p. 207−208 °C; UV 
(MeOH) λmax/nm: 233 and 296, log ε/dm3 mol−1 cm−1: 
4.12 and 4.19; IR(KBr) ῦmax/cm−1: 3195 (m), 3095 (m), 
2990 (w), 2950 (m), 2160 (w), 1745 (m), 1715 (s), 
1695 (s), 1625 (m), 1450 (m), 1385 (m), 1375 (m), 
1355 (m), 1245 (m), 1230 (s), 1210 (m), 1160 (m), 
1105 (m), 1080 (s), 1060 (m), 1040 (m); 1H NMR 
(CDCl3) δ/ppm: 9.85 (brs, 1H, NH-3'), 7.54 (s, 1H, H-
6'), 5.02 (s, 1H, H-1), 4.68 (brs, 2H, H-2 and H-3), 
4.51 (dd, 1H, J4,5a = 5.6, J4,5b = 8.5 Hz, H-4), 4.21 (dd, 
1H, J5a,4 = 5.6, Ja,b = 14.1 Hz, H-5a), 3.49 (dd, 1H, J5b,4 
= 8.5, Jb,a = 14.1 Hz, H-5b), 3.44 (s, 3H, CH3O), 1.47 
(s, 3H, CH3C), 1.33 (s, 3H, CH3C), 0.21 (s, 9H, 
(CH3)3Si); 13C NMR (CDCl3) δ/ppm: 161.57 (s, C-4'), 
149.67 (s, C-2'), 148.47 (d, C-6'), 112.76 (s, O−C−O), 
110.61 (d, C-1), 99.55 (s, CC), 99.15 (s, CC), 94.98 
(s, C-5'), 84.82 (d, C-3), 83.69 (d, C-4), 81.49 (d, C-2), 
55.93 (q, CH3O), 51.47 (t, C-5), 26.19 (q, CH3C), 
24.77 (q, CH3C), 0.00 ((CH3)3Si). Anal. Calcd. mass 
fractions of elements, w/%, for C18H26N2O6Si (Mr = 
394.50) are: C 54.80, H 6.64, N 7.10; found: C 54.58, 
H 6.61, N 7.07.  
Methyl 5-deoxy-5-(2,4-dioxo-5-acetylpyrimidin-1H-1-
yl)--D-ribofuranoside (17) 
Method A: Following the general procedure for the 
hydrolysis of isopropylidene protecting group: from 
reversed nucleoside 16 (369 mg, 0.94 mmol) the prod-
uct was crystallized from methanol to afford 217 mg 
(78 %) of 17 as white crystals: Rf = 0.42 
(CH2Cl2/MeOH 9:1); m.p. 189−190 oC; UV (MeOH) 
λmax/nm: 228 and 290, log ε/dm3 mol−1 cm−1: 3.99 and 
4.06; IR(KBr) ῦmax/cm−1: 3440 (w), 3000 (w), 1730 (s), 
1710 (s), 1685 (s), 1675 (s), 1605 (m), 1470 (m), 1430 
(w), 1385 (m), 1365 (m), 1330 (m), 1250 (w); 1H 
NMR (DMSO-d6) δ/ppm: β-anomer: 11.65 (brs, 1H, 
NH-3'), 8.31 (s, 1H, H-6'), 5.16 (d, 1H, J = 4.3 Hz, 
OH), 5.05 (d, 1H, J = 6.5 Hz, OH), 4.63 (s, 1H, H-1), 
4.16 (dd, 1H, J = 13.7 Hz, J = 3.4 Hz, H-5a), 
4.04−3.91 (m, 1H, H-5b), 3.91−3.77 (m, 2H, H-4, H-
3), 3.74 (t, 1H, J = 4.1 Hz, H-2), 3.22 (s, 3H, OCH3), 
2.46 (s, 3H, COCH3); 13C NMR (DMSO-d6) δ/ppm: β-
anomer: 194.40 (s, COCH3), 162.14 (s, C-4'), 153.20 
(d, C-6'), 150.23 (s, C-2'), 111.45 (s, C-5'), 109.09 (d, 
C-1), 79.80 (d, C-4), 74.22 (d, C-2), 72.35 (d, C-3), 
55.53 (q, CH3O), 51.30 (t, C-5), 30.54 (q, CH3CO). 
Anal. Calcd. mass fractions of elements, w/%, for 
C12H16N2O7 (Mr = 300.27) are: C 48.00, H 5.37, N 
9.33; found: C 47.93, H 5.40, N 9.40. 
Method B: Reversed nucleoside 16 (400 mg, 1.01 
mmol) was stirred at room temperature for 4 h in a 2:1 
mixture of TFA/H2O (20 mL). After evaporation of 
volatiles, the crude residue was purified by flash 
chromatography (CH2Cl2/MeOH 9:1). The product 
was crystallized from methanol to afford 237 mg (78 
%) of 17 as white crystals. The spectral properties 
were identical with a sample synthesized by method A. 
Method C: Reversed nucleoside 18 (350 mg, 1.09 
mmol) was stirred at room temperature for 3 h in a 2:1 
mixture of TFA/H2O (20 mL). After evaporation of 
volatiles, the crude residue was purified by flash chro-
matography (CH2Cl2/MeOH 9:1). The product was 
crystallized from methanol to afford 317 mg (97 %) of 
17 as white crystals. The spectral properties were iden-
tical with a sample synthesized by method A.  
Methyl 5-deoxy-5-(2,4-dioxo-5-ethynylpyrimidin-1H-1-
yl)-2,3-O-isopropylidene--D-ribofuranoside (18) 
A solution of (trimethylsilyl)ethynyl derivative 16 
(107 mg, 0.27 mmol) in 0.2 M solution of sodium 
methoxide in methanol (5.5 ml) was stirred 30 min at 
room temperature. The solution was carefully neutral-
ized by addition of Amberlite IR-120 (H+) ion ex-
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change resin until moistened pH paper indicated pH ≈ 
6. The mixture was filtered and the resin was washed 
with methanol. The combined filtrate was evaporated 
and the product was crystallized from CH2Cl2/hexane 
to afford 72 mg (88 %) of 18 as white crystals: Rf = 
0.43 (diethyl ether); m.p. 211−212 °C; UV (MeOH) 
λmax/nm: 227 and 290, log ε/dm3mol−1cm−1: 3.80 and 
3.87; IR(KBr) ῦmax/cm−1: 3270 (m), 3200 (w), 2100 
(vw), 1710 (s), 1680 (s), 1630 (s), 1460 (s), 1435 (m), 
1405 (w), 1385 (m), 1375 (m), 1370 (m), 1240 (m), 
1205 (m) cm−1; 1H NMR (CDCl3) δ/ppm: 8.75 (brs, 
1H, NH-3'), 7.57 (s, 1H, H-6'), 5.01 (s, 1H, H-1), 4.66 
(brs, 2H, H-2 and H-3), 4.50 (dd, 1H, J4,5a = 5.1 Hz, 
J4,5b = 8.7 Hz, H-4), 4.22 (dd, 1H, J5a,4 = 5.1 Hz, Ja,b = 
14.1 Hz, H-5a), 3.49 (dd, 1H, J5b,4 = 8.7 Hz, Jb,a = 14.1 
Hz, H-5b), 3.44 (s, 3H, CH3O), 3.17 (s, 1H, CCH), 
1.47 (s, 3H, CH3C), 1.33 (s, 3H, CH3C); 13C NMR 
(CDCl3) δ/ppm: 161.31 (s, C-4'), 149.48 (s, C-2'), 
148.85 (d, C-6'), 113.03 (s, O−C−O), 110.93 (d, C-1), 
98.61 (s, C-5'), 84.98 (d, C-3), 83.95 (d, C-4), 81.92 (s, 
CCH), 81.70 (d, C-2), 74.25 (d, CCH), 56.20 (q, 
CH3O), 51.85 (t, C-5), 26.38 (q, CH3C), 24.87 (q, 
CH3C). Anal. Calcd. mass fractions of elements, w/%, 
for C15H18N2O6 (Mr = 322.31) are: C 55.89, H 5.63, N 
8.69; found: C 55.68, H 5.73, N 8.62. 
 
Cell culturing and MTT test28,29 
Reversed nucleoside derivatives 12−15 and 17, in a 
parallel with 5-fluorouracil 5 as a standard antitumor 
drug, were selected for preliminary in vitro testing on 
cytotoxicity using 6 different human tumor cell lines: 
cervix adenocarcinoma (HeLa), pancreatic carcinoma 
(MIAPaCa2), laryngeal carcinoma (Hep-2), human 
caucasian bronchioalveolar carcinoma (NCI-H358), and 
colon carcinoma (HT-29, CaCo2). The cells were grown 
in monolayer at 37 oC in a humidified atmosphere with 
5 % CO2 in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10 % (v/v) fetal bovine 
serum, 2 mM glutamine, 100 U penicillin and 100 
mg/mL streptomycin. Cell lines were incubated with 
four 10-fold dilutions (10−4 to 10−7 M). After 72 hours 
of incubation the cell growth rate was evaluated using 
the MTT assay. 
For the MTT test, cells were seeded on 96 micro 
well flat bottom plates (Greiner, Austria) at 2×104 
cells/mL. After 72 hours of incubation with the tested 
compounds MTT (Merck, Germany) was added. DMSO 
(Merck, Germany) was used to dissolve the formed 
MTT-formazane crystals. Absorbency was measured at 
570 nm on Stat fax 2100 plate reader (Awareness Tech-
nology Inc. USA). All experiments were performed 
three times in triplicates. The percentage of treated 
tumor cells growth inhibition was calculated relative to 
the growth of untreated (control) cells. 
RESULTS AND DISCUSSION 
The synthetic approach to reversed nucleoside ana-
logues is based on the preparation of the already known, 
suitably protected methyl ribofuranoside 2 (73 %) and 
its transformation into 5-tosyl derivative 3 (76 %) by 
adopting the methods described in the literature 
(Scheme 1).23,24 Following our previously described 
approach to reversed nucleosides, the sodium salts of 
the uracil derivatives 4−6 were reacted with ribo-
furanoside 3 giving the corresponding reversed nucleo-
sides 7, 8 and 10 (Scheme 1).19,21 
It was reported that the condensation of thymine 
sodium salt with the tosyl monosaccharide 3 gave two 
regioisomers containing the ribofuranoside attached at 
N1′ or N3′ position of the thymine ring.30 However, we 
were not able to identify formation of the N-3′-
regioisomer in the reaction of uracil derivatives 4−6 
with 3 and, exclusively the corresponding N-1′-
regioisomers 7, 8 and 10 were isolated. The structures 
of the reversed nucleosides 7, 8 and 10 were confirmed 
by NMR, FTIR and elemental analyses. The formation 
of the N-1′- and not the N-3′-regioisomers of 7, 8 and 10 
is apparent from their 1H NMR spectra. In the spectrum 
of 7, the signal of C5′ proton appears as a doublet of 
doublets due to the vicinal H5′-H6′ coupling (J5',6' = 7.9 
Hz) and the additional long-range H5'-NH3' coupling 
(J5',NH-3' = 2.1 Hz), the latter excluding the N-3′-regional 
isomer structure. In addition, in the spectra of 7, 8 and 
10 the NH proton signals appear at δ 9.38; 11.7 and 
11.87 ppm, respectively, being the characteristic chemi-
cal shifts of the uracil NH-3′ protons. 
5-Fluorouracil 5 is well known to exhibit a strong 
antitumor activity but its toxicity largely limits the use 
of 5 as a practical antitumor agent for humans.31 We 
examined the possibility to prepare the reversed nucleo-
side 8 incorporating 5-fluorouracil fragment. The sodi-
um salt of 5-fluorouracil 5 was condensed with tosyl 
ribofuranoside 3 giving the N-1′-regioisomer of reversed 
nucleoside 8 in 23 % yield and also the novel N-1′,N-3′-
disubstituted nucleoside 9 in 25 % yield. In the 1H NMR 
spectra of both, 8 and 9 the signal of H-6′ vinyl proton 
is split into a doublet (8:  = 8.08 ppm, 3JH6'-F = 6.9 Hz; 
9:  = 8.19 ppm, 3JH6'-F = 6.5 Hz) due to the H-F cou-
pling. 
Since the yields of the reversed nucleosides 7 and 
8 prepared from uracil 4 and 5-fluorouracil 5 sodium 
salts were relatively low, we examined the condensation 
of tosyl ribofuranoside 3 with the 5-iodouracil 6 which 
upon N1′-deprotonation should be better nucleophile 
compared to the corresponding anions of 4 and 5, due to 
electron donating effect of iodine. The N-1′-regioisomer 
10 was obtained in 58 % yield together with the very 
small amount of the novel N-1',N-3'-disubstituted nucle-
oside derivative 11 (1.5 %). The hydrogenation of 10 
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using Pd/C catalyst afforded the reversed nucleoside 7 
in 82 % yield (Scheme 1). By the latter two step prepa-
ration, 7 could be prepared in higher yield than in the 
direct condensation of the sodium salt of uracil 4 with 3. 
The 1H NMR spectra of the isopropylidene pro-
tected reversed nucleosides 7, 8 and 10 as well as those 
of the equally protected N-1′,N-3′-disubstituted nucleo-
sides 9 and 11 conclusively show that all posses the -
configuration. In each spectrum, the anomeric C1 pro-
ton appears as the singlet due to small coupling constant 
with the proton at C2 ribose. 
The isopropylidene protecting groups of 7−10 
were removed by using of Amberlite IR-120 (H+) ion 
exchange resin in refluxing methanol to yield the cor-
responding methyl ribofuranoside reversed nucleo-
sides (12−15) in 65−89 % yields (Scheme 1). The 1H 
NMR spectrum of 14 reveal the presence of duplicate 
peaks for H-6' proton due to the presence of an ano-
meric mixture in the ratio / = 1:10 and in the spec-
trum of 13 signals of protons at C1 position (/ = 
3:10) are well separated as shown in the inset of 
Scheme 1. 
The 5'-iodo reversed nucleoside 10 is suitable 
for further functionalization at the uracil ring. It is 
well known that the coupling of terminal alkynes 
with 5-iodouracil nucleosides proceeds in high yields 
in the presence of palladium catalyst.32 Treatment of 
10 with ethynyltrimethylsilane and (PPh3)PdCl2 in 
the presence of CuI and triethylamine afforded 16 in 
71 % yield (Scheme 2). The structure of 16 was con-
firmed by the presence of acetylenic band in the IR 
spectrum ( 2160 cm−1) and further supported by the 
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Scheme 1. (a) 1. HCl/MeOH, 2. 2,2-dimethoxypropane, acetone; (b) TsCl/Py; (c) NaH/DMF; (d) H2, Pd/C, 0.1 M NaOH, MeOH;
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tra (inset). 
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1H NMR and elemental analysis (see Experimental 
part). 
Using acidic ion exchange resin in methanol or 50 
% aqueous TFA for isopropylidene and trimethylsilyl 
deprotection of 16 gave 5'-acetyl reversed nucleoside 17 
in 78 % yield. As it was described in the literature 5-
ethynyl-2'-deoxyuridine could be hydrated by dilute 
sulphuric acid to give 5-acetyl derivative in high 
yield.33,34 Hence, during deprotection of 16, under acidic 
conditions besides removal of isopropylidene and trime-
thylsilyl groups the addition of water on the acetylenic 
bond occurred giving the 5'-acetyl derivative 17. Treat-
ment of 16 with 0.2 M sodium methoxide in dry metha-
nol effected removal of the trimethylsilyl group giving 
5'-ethynyl reversed nucleoside 18 in 88 % yield. The 
removal of isopropylidene group of 18 by 50 % aqueous 
TFA gave the 5'-acetyl 17 in almost quantitative yield 
(Scheme 2). 
The reversed nucleosides 12−15 and 17 were 
evaluated for their antitumor activity in vitro against 
HeLa, MIAPaCa2, Hep2, NCI-H358, CaCo-2, and HT-
29 cell lines using 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl-2H-tetrazoliumbromide (MTT) assay meth-
od.28,29 The reference drug used was 5-fluorouracil. The 
activity of the samples and the reference drug was as-
sayed under identical conditions at concentrations of 
10−4 M to 10−7 M. 
Among the tested compounds only 5'-iodo re-
versed nucleoside 14 (Figure 1) showed a moderate 
cytostatic activity against CaCo-2 cell line (50 % 
growth inhibition c =10−4 M and 30 % growth inhibition 
c = 10−610−7 M), which indicates that further synthetic 
variations of 14 may result in the preparation of deriva-
tives with improved cytostatic potential. 
 
CONCLUSIONS 
In this work we describe the synthetic approach to re-
versed nucleosides which enables their preparation in 
gram quantities. The reaction of the sodium salt of vari-
ous pyrimidine nucleobases 4−6 with a suitably protect-
ed ribofuranoside 3, enable the efficient preparation of 
the reversed pyrimidine nucleosides (7, 8, 10). In some 
cases also N-1,N-3-diribofuranosyl substituted nucleo-
sides 9 and 11 were isolated. The 5'-iodo reversed nu-
cleoside 10 was suitable for further functionalization at 
the uracil and by using the Sonogashira coupling 5'-
ethynyl reversed nucleoside 16 was synthesized and 
transformed to 5'-acetyl derivative 17 under acidic con-
ditions. The reversed nucleosides 12−15 and 17 were 
tested for the antiproliferative activity on the panel of 
six cell lines (HeLa, MIAPaCa2, Hep2, NCI-H358, 
CaCo-2, and HT-29). Modest growth inhibition was 
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Scheme 2. (a) PdCl2(PPh3)2, CuI, Et3N; (b) Amberlite IR-120 (H+), MeOH, reflux; (c) NaOMe/MeOH, rt; (d) 50 % TFA/H2O. 
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obtained only for compound 14 and the CaCo-2 cell line 
at the highest concentration regime (50 % growth inhi-
bition c =10−4 M). 
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